Shield Therapeutics ’s Q3 trading update for Accrufer in the US market shows that the Viatris partnership and expanded sales force, which was only fully in-place and trained from mid-2023, is bearing fruit. KPIs such as total scrips, new scrips, retention rate and net realised price are all looking very positive versus H1 2023.
